It's all About the Data and MetaData

CDISC 101 – A clinical trial data management standards primer

 Email Article  

Tweet  

  

  

 delicious  

  

The Clinical Data Interchange Standards Consortium (CDISC) is a non-profit group that defines clinical data standards for the pharmaceutical industry. CDISC has developed numerous data models. Four of these models are of particular importance: 

Study Data Tabulation Model (SDTM). The SDTM defines the data tabulation data sets that are to be sent to the FDA as part of a regulatory submission. The FDA has endorsed the SDTM in its Electronic Common Technical Document (eCTD) guidance. The SDTM was originally designed to simplify the production of case report tabulations (CRTs), and therefore the SDTM is listing friendly, but not necessarily friendly for creating statistical summaries and analysis. 

Analysis Dataset Models (ADaM). The CDISC ADaM standard defines data set definition guidance for the analysis data structures. These data sets are designed for creating statistical summaries and analysis. DZS/Clinplus has developed an extremely powerful SDTM to ADaM conversion tool to make this process much more user friendly. Please go to: http://www.clinplus.com/products/new-report-/ for more information. 

Operational Data Model (ODM). The ODM is a powerful XML-based data model that allows for XML-based transmission of any data involved in the clinical trials. SAS has provided support for importing and exporting ODM files via the CDISC procedure and the XML LIBNAME engine. 

Case Report Tabulation Data Definition Specification (Define.xml). Define.xml is the replacement for the data definition file (define.pdf) sent to the FDA in electronic submissions. Define.xml is based on the CDISC ODM model and is intended to provide a machine-readable version of define.pdf.Because define.xml is machine readable, the metadata about the submission data sets can be easily read by computer applications. This allows the FDA to work more efficiently with the data submitted to it. Exporting, importing, and creating data for these models is most important.

The FDA has begun to formally endorse the use of these data models in their guidance. Eventually the FDA will probably require data to be formatted to the CDISC model standards for all regulatory submissions.

There is also another blog article at: http://www.clinplus.com/-Data-and-MetaData-DZS-software/bid/29783/Need-to-convert-SDTM-data-to-ADaM-data-Here-s-How